A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...

In the 2000s, cost-effectiveness analysis said it was a bad use of money to send antiretroviral drugs to low-income countries—drugs that ended up saving millions of lives.

The UK is being asked for £1.8 billion, making this one of the biggest decisions facing James Cleverly, the new Secretary of State, within his first two weeks of the job. We will review what is known about the FCDO’s likely commitment, and recommend four key questions that the new Secretary of State...

PEPFAR’s new strategy—to be released in final form later this year—focuses on how to accelerate progress toward epidemic control amidst continued impacts from COVID-19, while also strengthening core health system functions as well as partnership and coordination efforts; this is precisely what the c...

This World AIDS Day, Mead Over and Julia Kaufman examine the positive spillover effects of treating HIV.

PEPFAR has long enjoyed bipartisan support on the Hill. Yet, it has not been spared from significant cuts in President Trump’s latest budget request for foreign aid. It is noteworthy that this administration’s three successive budget requests have proposed increasingly large cu...

On World AIDS Day, December 1, we honor the advocates that transformed HIV/AIDS from a death sentence to a chronic disease. These activists bequeathed a golden age of global health—a boom in money and programs that is sustained today, evidenced by the recent reauthorization of PEPFAR. But...

In July, United States Global AIDS Coordinator Deborah Birx made a striking commitment: under her leadership, the President’s Emergency Plan for AIDS Relief (PEPFAR) would direct at least 40 percent of its funding to host country governments or organizations by the end of 2019—rising to ...

We finally have some clarity on PEPFAR’s new “acceleration” strategy toward epidemic control: a lot more allocated to a few countries, and a lot less for others.